Functional Iron Deficiency

Definition and Pathophysiology

• Functional iron deficiency occurs when there is insufficient iron available for hemoglobin synthesis despite adequate iron stores, typically due to impaired mobilization of iron from storage sites to support increased erythropoiesis demands, as noted by the American Journal of Kidney Diseases 1, 2
• Absolute iron deficiency is characterized by depleted iron stores and impaired iron delivery to erythroid marrow, with low serum ferritin and transferrin saturation, according to the American Journal of Kidney Diseases 1, 2

Causes of Functional Iron Deficiency

• Pharmacological stimulation of erythropoiesis, most commonly seen during treatment with erythropoiesis-stimulating agents like Epoetin, can lead to functional iron deficiency, as reported by the American Journal of Kidney Diseases 1
• Chronic inflammation increases hepcidin production, blocking iron absorption and impairing iron mobilization from storage sites, as noted by the European Journal of Heart Failure 3, 4
• Chronic heart failure affects 40-70% of CHF patients due to systemic inflammation and elevated hepcidin levels, according to the European Journal of Heart Failure 3, 4
• Chronic kidney disease is common in patients undergoing dialysis and receiving ESA therapy, as reported by the American Journal of Kidney Diseases 1, 2, 5

Laboratory Findings

• Transferrin saturation is decreased to levels consistent with iron deficiency, according to the American Journal of Kidney Diseases 1, 2
• Serum ferritin is normal or elevated, often between 100-700 ng/mL, as noted by the American Journal of Kidney Diseases 1, 2
• Erythrocyte protoporphyrin concentration is increased due to limited iron availability for hemoglobin synthesis, as reported by MMWR Recommendations and Reports 6, 7, 8

Clinical Significance

• Functional iron deficiency impairs response to ESA therapy, requiring higher doses to achieve target hemoglobin levels, according to the American Journal of Kidney Diseases 1, 2
• Reduced exercise capacity and quality of life are particularly important in chronic heart failure patients, as noted by the European Journal of Heart Failure 3, 4
• Increased hospitalization risk is seen in heart failure patients with functional iron deficiency, according to the European Journal of Heart Failure 3, 4
• Developmental delays can occur in pediatric patients with chronic conditions, as reported by MMWR Recommendations and Reports 6, 7, 8

Management

• Intravenous iron supplementation is preferred over oral iron in most cases, especially in CKD patients on ESA therapy, according to the American Journal of Kidney Diseases 1, 2, 5
• Weekly IV iron (50-125 mg) until target hemoglobin is achieved or iron parameters normalize is a recommended dosing strategy, as noted by the American Journal of Kidney Diseases 1, 2
• Regular assessment of hemoglobin, TSAT, and ferritin levels is essential to guide therapy, according to the American Journal of Kidney Diseases 1, 2, 5
• Addressing underlying causes, such as managing chronic inflammation, is crucial in the management of functional iron deficiency, as reported by the European Journal of Heart Failure 3, 4

Iron Deficiency Diagnosis and Treatment

Definitions and Diagnostic Criteria

• The National Kidney Foundation defines absolute iron deficiency as TSAT <20% AND ferritin <100 ng/mL for non-dialysis and peritoneal dialysis patients, and TSAT <20% AND ferritin <200 ng/mL for hemodialysis patients 9, 10
• In healthy individuals without inflammation, ferritin <12 ng/mL indicates depleted stores, according to the American Journal of Kidney Diseases 9
• For surgical patients, ferritin must exceed 30 ng/mL to achieve 92% sensitivity for excluding absolute iron deficiency, as recommended by the British Journal of Anaesthesia 11, 12

Pathophysiology

• Functional iron deficiency is characterized by TSAT <20% with ferritin >100 ng/mL, and occurs when iron stores are adequate but cannot be mobilized quickly enough to meet the demands of erythropoiesis, as stated by the American Journal of Kidney Diseases 9, 10
• The Kidney International journal notes that two distinct mechanisms exist for functional iron deficiency: inflammation-mediated iron sequestration and kinetic iron deficiency from ESA-stimulated erythropoiesis 13, 10

Distinguishing Between Functional Iron Deficiency and Inflammatory Block

• The American Journal of Kidney Diseases recommends that when uncertain, administer weekly IV iron (50-125 mg) for 8-10 doses to distinguish between functional iron deficiency and inflammatory block 9
• If no erythropoietic response occurs, inflammatory block is most likely, and IV iron should be discontinued until the inflammatory condition resolves 9

Treatment Approaches

• The British Journal of Anaesthesia suggests that a therapeutic trial of oral iron confirms absolute iron deficiency, and that intravenous iron is indicated when oral iron intolerance or poor absorption occurs 11, 12
• The American Journal of Hematology recommends IV iron monotherapy or combination therapy with IV iron plus ESA for cancer patients with functional iron deficiency 14
• The American Journal of Kidney Diseases notes that approximately 400-500 mg of supplemental iron is needed every 3 months to maintain adequate stores once target hemoglobin is reached 9

Important Caveats

• The Kidney International journal states that current diagnostic parameters have significant limitations, and that TSAT and ferritin are not reliable for estimating body iron stores or predicting response to therapy 13, 10
• The British Journal of Anaesthesia notes that ferritin is an acute-phase reactant, making interpretation difficult in inflammatory conditions, and that traditional thresholds are unsuitable for patients with any inflammatory process 11, 12

Diagnosis and Management of Iron Deficiency Anemia in Chronic Kidney Disease, Heart Failure, and Inflammatory Bowel Disease

Definitions

• Absolute iron deficiency is defined by transferrin saturation (TSAT) ≤ 20 % together with ferritin < 100 ng/mL in non‑dialysis or peritoneal‑dialysis chronic kidney disease (CKD) patients, or ferritin < 200 ng/mL in hemodialysis patients【15】.
• Functional iron deficiency occurs when iron stores are adequate (ferritin > 100 ng/mL in non‑dialysis CKD or > 200 ng/mL in hemodialysis) but TSAT remains ≤ 20 % because iron cannot be mobilized rapidly enough for erythropoiesis【15】.

Pathophysiology

• Functional iron deficiency arises from two mechanisms: (1) Inflammation‑mediated hepcidin elevation that blocks intestinal iron absorption and traps iron in macrophages, and (2) Kinetic iron deficiency where erythropoiesis‑stimulating agents (ESAs) create a sudden iron demand that exceeds the rate of iron release from stores【15】.

Laboratory Diagnosis

• TSAT ≤ 20 % is a hallmark of both absolute and functional iron deficiency【15】.
• Ferritin thresholds differentiate the two states: < 100 ng/mL (or < 200 ng/mL for hemodialysis) indicates absolute deficiency, whereas > 100 ng/mL (or > 200 ng/mL for hemodialysis) with low TSAT suggests functional deficiency【15】.
• Reticulocyte hemoglobin content is reduced in absolute deficiency and also lowered in functional deficiency, reflecting insufficient iron for new red cells【15】.
• Soluble transferrin receptor (sTfR) is a more reliable marker in inflammatory conditions because it rises with true iron deficiency but is not affected by inflammation【16】.
• Ferritin interpretation in inflammation: values up to 100 µg/L may still represent iron deficiency when inflammation is present【17】.

Treatment of Absolute Iron Deficiency

• Oral iron (≈ 100 mg elemental iron daily) is recommended for patients without malabsorption or intolerance【17】.
• Intravenous (IV) iron is indicated when oral iron is poorly tolerated, when malabsorption exists, or when chronic inflammation limits oral absorption【16】.
• Expected therapeutic response: hemoglobin rise of 1–2 g/dL within 4–8 weeks after initiating therapy【16】.

Treatment of Functional Iron Deficiency

• IV iron is strongly preferred over oral iron in most settings, especially for CKD patients on ESA therapy, because hepcidin‑mediated blockade limits oral absorption【15】【16】.
• Dosing strategy: weekly IV iron 50–125 mg for 8–10 doses until target hemoglobin and iron parameters are achieved【16】.
• In chronic heart failure, IV iron (e.g., ferric derisomaltose) has demonstrated a significant reduction in cardiovascular death, whereas oral iron showed no benefit and should be avoided【17】【16】.

Monitoring and Safety

• Laboratory follow‑up should include hemoglobin, TSAT, and ferritin 4–8 weeks after the last IV infusion; testing within 4 weeks of a total‑dose infusion can give falsely elevated iron values【16】.
• In hemodialysis patients, TSAT and ferritin should be checked at least every 3 months to guide ongoing therapy【15】.

Special Populations

Chronic Kidney Disease

• Between 15 % and 73 % of non‑dialysis CKD patients have either ferritin < 100 µg/L or TSAT < 20 %, indicating a high prevalence of iron deficiency【15】.

Inflammatory Bowel Disease

• Approximately one‑third of patients with active IBD exhibit iron deficiency【17】.
• Oral iron should be limited to ≤ 100 mg elemental iron daily; IV iron is recommended for those with intolerance or moderate‑to‑severe anemia (hemoglobin < 100 g/L)【17】.

Chronic Heart Failure

• IV iron (specifically ferric derisomaltose) is the first formulation shown to significantly lower cardiovascular mortality in heart‑failure patients with functional iron deficiency【16】.